Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS 46 Median PS Value is A$0.55 as of Jul. 14, 2026, which is 100% below its 10-year median of 0.82. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 278 Biotechnology companies, BLS Pharmaceuticals ranks worse than 86.69% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for BLS Pharmaceuticals's Median PS Value or its related term are showing as below:
ASX:BLS'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26 Med: 0.82 Max: 5
Current: 1.76
During the past 13 years, the highest Price to Median PS Value of BLS Pharmaceuticals was 5.00. The lowest was 0.26. And the median was 0.82.
ASX:BLS's Price-to-Median-PS-Value is ranked worse than 86.69% of 278
companies
in the Biotechnology industry
Industry Median: 0.63
vs ASX:BLS: 1.76
BLS Pharmaceuticals (ASX:BLS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BLS Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.97
/
0.55
=
1.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals Median PS Value Related Terms
BLS Pharmaceuticals Median PS Value Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.7919.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.197.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a Median PS Value of A$0.55 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BLS Pharmaceuticals and its competitors. This is 33% below median its historical median of 0.82. Over the past decade, BLS Pharmaceuticals' Median PS Value has ranged from 0.26 to 5.00. According to the industry distribution chart, BLS Pharmaceuticals ranks #241 out of 278 companies in the Biotechnology industry, placing it in the top 86.7%.
Is BLS Pharmaceuticals' Median PS Value too high?
BLS Pharmaceuticals' current Median PS Value of A$0.55 is 33% below median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 5.00. Based on the distribution chart, BLS Pharmaceuticals ranks #241 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Median PS Value compare to KHC and GIS?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #241 out of 278 companies for Median PS Value. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Median PS Value is 0.63. Historically, BLS Pharmaceuticals' own Median PS Value has ranged from 0.26 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Median PS Value is A$0.55, which is 33% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Median PS Value is A$0.55, which is 33% below median its 10-year median of 0.82. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Median PS Value is A$0.55 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Median PS Value: A$0.55 (33% below median its 10-year median of 0.82)
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
